Bernstein analyst Lee Hambright has maintained their neutral stance on JNJ stock, giving a Hold rating on October 3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lee Hambright has given his Hold rating due to a combination of factors that reflect both opportunities and challenges for Johnson & Johnson. The company has demonstrated strong performance by achieving its Innovative Medicine sales target of $57 billion a year ahead of schedule, and it is now guiding investor expectations towards the higher end of its long-range plan for 2025-2030. This growth is supported by a diverse portfolio of products across oncology, immunology, and neuroscience, with several promising treatments recently approved or filed with the FDA.
Despite these positive developments, the Hold rating reflects a balanced view of the company’s prospects. While Johnson & Johnson is navigating the macroeconomic environment effectively and has committed significant investments in U.S. manufacturing, the stock’s current valuation and the potential risks associated with market dynamics justify a cautious stance. The price target has been adjusted upwards to $193, reflecting an improved outlook, but the Hold rating suggests that investors should wait for more favorable conditions before considering a stronger buy position.
In another report released on October 3, Bank of America Securities also maintained a Hold rating on the stock with a $198.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year.